Table II.
EBRT patients | |||||||
---|---|---|---|---|---|---|---|
Baseline (N = 47) | Midpoint of EBRT (N = 47) |
Wilcoxon Sign Rank Test | |||||
Proteins | Mean ± SE | Median | Mean ± SE | Median | Z | P value | Effect size (r) |
Fatigue score (FACT-F) | 43.95 ± 1.28 | 47.00 | 38.36 ± 1.52 | 39.50 | −3.590 | 0.000 | 0.37 |
Glial cell derived neurotrophic factor (GDNF) (ng/mL) | 2.01 ± 1.22 | 0.13 | 1.49 ± 0.80 | 0.13 | −1.18 | 0.24 | 0.12 |
Brain derived neurotrophic factor (BDNF) (ng/mL) | 1.10 ± 0.12 | 0.86 | 0.84 ± 0.10 | 0.82 | −2.30 | 0.02* | 0.24 |
SNARE-associated protein (SNAPIN) (pg/mL) | 34.95 ± 7.33 | 20.29 | 34.95 ± 8.72 | 20.13 | −0.01 | 0.99 | 0.00 |
Levels of fatigue as measured by the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) scale and plasma concentrations of neurotrophic factors measured in ng/mL during external beam radiation therapy (EBRT) are presented as mean with standard error (SE) and median.
Changes in fatigue and neurotrophic factors are indicated by standard scores or z scores, and significant difference between time points indicated by * P < 0.05 and effect size (r).